|
시장보고서
상품코드
2049605
말라리아 진단 시장 보고서 : 기술별, 용도별, 지역별(2026-2034년)Malaria Diagnostics Market Report by Technology (Microscopy, Rapid Diagnostic Tests (RDTs), Molecular Diagnostic Tests), End Use (Hospital, Clinics, Diagnostic Centers), and Region 2026-2034 |
||||||
세계의 말라리아 진단 시장 규모는 2025년에 9억 2,460만 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 14억 8,620만 달러에 달하고, 2026년부터 2034년까지 CAGR 5.25%로 성장할 것으로 예측했습니다.
말라리아 진단은 개인의 감염 여부를 확인하기 위해 시행하는 임상 검사를 말합니다. 말라리아는 감염된 암컷 Aedes aegypti 모기에 물려 말라리아 원충이 체내로 침입해 발생합니다. 일반적인 증상으로는 발열, 피로감, 메스꺼움, 두통 등이 있습니다. 이 감염은 다양한 신속 진단법, 현미경 검사 및 분자진단 검사를 통해 진단됩니다. 이러한 검사에는 간접면역형광법(IFA)과 효소면역측정법(ELISA)을 이용한 항원 검출 및 혈청학적 방법이 사용되고 있습니다. 병원, 검사실, 진료소, 연구소, 진단센터 등에서 널리 사용되고 있습니다.
말라리아 진단 시장 동향:
전 세계 말라리아의 확산은 시장 전망을 밝게 만드는 주요 요인 중 하나입니다. 말라리아는 생명을 위협하는 전염병으로, 특히 개발도상국에서 많은 소중한 생명을 앗아가고 있습니다. 그러나 말라리아 진단법과 치료법에 대한 일반인들의 인식이 높아지면서 시장 성장에 힘을 실어주고 있습니다. 의료기관과 진단 검사실에서는 기생충의 각 단계를 식별하고 적절한 치료 계획을 수립하기 위해 현미경 진단을 광범위하게 채택하고 있습니다. 또한, 말라리아 진단을 위한 정량적 버피코트법(QBC), 말초혈액도말법 개발 등 다양한 기술 발전도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 이에 따라 정확도 향상을 위한 POC(Point-of-Care) 진단기기의 보급도 시장 성장에 기여하고 있습니다. 그 외 일반 시민들의 의료비 부담 능력 향상, 정부의 공공보건 증진 정책 시행 등도 시장 성장을 견인할 것으로 예상됩니다.
본 보고서에서 답변하는 주요 질문
- 전 세계 말라리아 진단 시장 규모는 어느 정도인가?
- 2026년부터 2034년까지 세계 말라리아 진단 시장의 예상 성장률은 어느 정도가 될 것인가?
- 세계 말라리아 진단 시장을 이끄는 주요 요인은 무엇인가?
- COVID-19는 세계 말라리아 진단 시장에 어떤 영향을 미쳤는가?
- 기술별로 볼 때, 세계 말라리아 진단 시장은 어떻게 세분화되는가?
- 세계 말라리아 진단 시장은 최종 용도별로 어떻게 세분화되는가?
- 세계 말라리아 진단 시장의 주요 지역은 어디인가?
- 세계 말라리아 진단 시장의 주요 플레이어/기업은 어디인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 말라리아 진단 시장
제6장 시장 내역 : 기술별
제7장 시장 내역 : 최종사용별
제8장 시장 내역 : 지역별
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
KSMThe global malaria diagnostics market size reached USD 924.6 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,486.2 Million by 2034, exhibiting a growth rate (CAGR) of 5.25% during 2026-2034.
Malaria diagnostics refers to the clinical tests conducted to detect the presence of the infection in individuals. Malaria is caused by the bite of an infected female Anopheles mosquito, which leads to the transfer of Plasmodium parasites into the body. Some common symptoms include fever, fatigue, nausea and headaches. The infection is diagnosed through various rapid diagnostics, microscopy and molecular diagnostic tests. These tests use antigen detection and serology techniques using indirect immunofluorescence (IFA) or enzyme-linked immunosorbent assay (ELISA). They are widely used in hospitals, laboratories, clinics, research institutes and diagnostic centers.
MALARIA DIAGNOSTICS MARKET TRENDS:
The increasing prevalence of malaria across the globe is one of the key factors creating a positive outlook for the market. Malaria is a life-threatening infection that has caused a significant loss of human lives, especially in developing nations. However, rising awareness among the masses regarding the available diagnostic and treatment alternatives for malaria is providing a thrust to the market growth. Healthcare centers and diagnostic laboratories are widely adopting microscopic diagnostics to identify the parasite at different stages and design suitable treatment plans. Additionally, various technological advancements, such as the development of the Quantitative Buffy Coat (QBC) method and peripheral blood smear technique for diagnosing malaria, are acting as other growth-inducing factors. In line with this, the availability of Point-of-Care (POC) diagnostic devices for enhanced accuracy is also contributing to the growth of the market. Other factors, including rising healthcare expenditure capacities of the masses, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.
KEY MARKET SEGMENTATION:
Breakup by Technology:
- Microscopy
- Rapid Diagnostic Tests (RDTs)
- Molecular Diagnostic Tests
- Conventional PCR
- Real-Time PCR (qPCR)
Breakup by End Use:
- Hospital
- Clinics
- Diagnostic Centers
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Access Bio, Beckman Coulter Inc. (Danaher Corporation), bioMerieux SA (Compagnie Merieux Alliance), Bio-Rad Laboratories Inc., Nikon Corporation, Novartis AG, Olympus Corporation, Premier Medical Corporation Pvt. Ltd., Siemens Healthcare GmbH (Siemens AG), Sysmex Corporation and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report
- 1.How big is the global malaria diagnostics market?
- 2.What is the expected growth rate of the global malaria diagnostics market during 2026-2034?
- 3.What are the key factors driving the global malaria diagnostics market?
- 4.What has been the impact of COVID-19 on the global malaria diagnostics market?
- 5.What is the breakup of the global malaria diagnostics market based on the technology?
- 6.What is the breakup of the global malaria diagnostics market based on the end use?
- 7.What are the key regions in the global malaria diagnostics market?
- 8.Who are the key players/companies in the global malaria diagnostics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Malaria Diagnostics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Technology
- 6.1 Microscopy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Rapid Diagnostic Tests (RDTs)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Molecular Diagnostic Tests
- 6.3.1 Market Trends
- 6.3.2 Key Segments
- 6.3.2.1 Conventional PCR
- 6.3.2.2 Real-Time PCR (qPCR)
- 6.3.3 Market Forecast
7 Market Breakup by End Use
- 7.1 Hospital
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Clinics
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Diagnostic Centers
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Access Bio
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.3 Beckman Coulter Inc. (Danaher Corporation)
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 SWOT Analysis
- 13.3.4 bioMerieux SA (Compagnie Merieux Alliance)
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Bio-Rad Laboratories Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Nikon Corporation
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Novartis AG
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Olympus Corporation
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 Premier Medical Corporation Pvt. Ltd.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.10 Siemens Healthcare GmbH (Siemens AG)
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financials
- 13.3.10.4 SWOT Analysis
- 13.3.11 Sysmex Corporation
- 13.3.11.1 Company Overview
- 13.3.11.2 Product Portfolio
- 13.3.11.3 Financials
- 13.3.11.4 SWOT Analysis
- 13.3.12 Thermo Fisher Scientific Inc
- 13.3.12.1 Company Overview
- 13.3.12.2 Product Portfolio
- 13.3.12.3 Financials
- 13.3.12.4 SWOT Analysis
- 13.3.1 Abbott Laboratories
